Document is current
Any future updates will be listed below
-
Authors
Jansén-Storbacka, Laura R.
Honasoge, Kailas S.
Molnárová, Eva
Soboleva, Arina
Agema, Bram C.
Paats, Marthe S.
Moes, Dirk Jan A. R.
Veerman, G. D. Marijn
Barbaro, Alethea B. T.
Dobbe, Roel
Grossmann, Irene
Azimi, Sepinoud
Mathijssen, Ron H. J.
Dingemans, Anne-Marie C.
Staňková, Kateřina
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VI.Vidi.213.139)
European Commission (European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 955708)
- License Information
-
More Information
Article History
Received: 20 July 2025
Accepted: 14 January 2026
First Online: 5 February 2026
Declarations
:
: Ron Mathijssen received financial support (paid to institute) during the last 5 years from pharmaceutical companies Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Deuter Oncology, Echo Pharmaceuticals, Nordic Pharma, Novartis, Pamgene, Pfizer, Roche, Sanofi and Servier. All other authors have no competing interests.
